Literature DB >> 21841322

Serum dehydroepiandrosterone sulphate levels in patients with non-alcoholic fatty liver disease.

Masafumi Koga1, Hiroshi Saito, Mikio Mukai, Toshiji Saibara, Soji Kasayama.   

Abstract

BACKGROUND: Dehydroepiandrosterone (DHEA) is an adrenal hormone reported to prevent body weight gain, diabetes mellitus and atherosclerosis. We hypothesized that DHEA is involved in the pathophysiology of non-alcoholic fatty liver disease (NAFLD) often associated with obesity and insulin resistance. In this study, we aimed to examine the clinical significance of serum DHEA sulfate (DHEAS) in patients with NAFLD.
METHODS: We determined serum DHEAS, serum alanine aminotransferase (ALT), serum lipids, plasma fasting glucose and insulin levels in 158 Japanese men who had neither viral hepatic diseases nor alcohol intake exceeding 20 g/day. NAFLD was diagnosed by the presence of fatty change of the liver by echotomographic examination.
RESULTS: Among the study subjects, 69 were diagnosed as having NAFLD. Their serum DHEAS levels were significantly higher than in 89 subjects without NAFLD. Serum DHEAS levels in 19 NAFLD patients with elevated ALT levels (>40 U/L) were significantly higher than in the other 50 NAFLD patients with normal ALT levels (≤40 U/L). Multivariate regression analysis demonstrated that serum ALT was positively correlated with serum DHEAS, serum triglyceride and body mass index.
CONCLUSION: Serum DHEAS levels are increased in patients with NAFLD with elevated ALT levels. Increased serum DHEAS may be a component of the pathophysiology of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841322     DOI: 10.2169/internalmedicine.50.4682

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

Review 1.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

Review 2.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

3.  Downregulation of sulfotransferase expression and activity in diseased human livers.

Authors:  Emine B Yalcin; Vijay More; Karissa L Neira; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt; Roberta S King
Journal:  Drug Metab Dispos       Date:  2013-06-17       Impact factor: 3.922

4.  Steroid metabolomic signature of liver disease in nonsyndromic childhood obesity.

Authors:  Aneta Gawlik; Michael Shmoish; Michaela F Hartmann; Stefan A Wudy; Zbigniew Olczak; Katarzyna Gruszczynska; Ze'ev Hochberg
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

5.  Identification of new biomarker candidates for glucocorticoid induced insulin resistance using literature mining.

Authors:  Wilco Wm Fleuren; Erik Jm Toonen; Stefan Verhoeven; Raoul Frijters; Tim Hulsen; Ton Rullmann; René van Schaik; Jacob de Vlieg; Wynand Alkema
Journal:  BioData Min       Date:  2013-02-04       Impact factor: 2.522

Review 6.  Nonalcoholic fatty liver disease: Diagnostic biomarkers.

Authors:  Fatemeh Hadizadeh; Elham Faghihimani; Peyman Adibi
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.